Provided by Tiger Trade Technology Pte. Ltd.

Abivax S.A.

92.88
-2.2200-2.33%
Post-market: 92.80-0.0800-0.09%19:44 EDT
Volume:644.33K
Turnover:60.29M
Market Cap:8.09B
PE:-15.70
High:95.82
Open:95.82
Low:92.58
Close:95.10
52wk High:148.83
52wk Low:69.81
Shares:87.05M
Float Shares:75.47M
Volume Ratio:0.47
T/O Rate:0.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.9176
EPS(LYR):-5.6758
ROE:-252.35%
ROA:-62.88%
PB:19.61
PE(LYR):-16.36

Loading ...

Analysts Offer Insights on Healthcare Companies: HeartFlow, Inc. (HTFL), Taysha Gene Therapies (TSHA) and Abivax SA Sponsored ADR (ABVX)

TIPRANKS
·
Jun 30

Abivax Sa : Wedbush Raises Target Price to $110 from $90

THOMSON REUTERS
·
Jun 30

Wedbush Raises Price Target on Abivax to $110 From $90, Keeps Neutral Rating

MT Newswires Live
·
Jun 30

Top Premarket Gainers

MT Newswires Live
·
Jun 30

Stocks to Watch: Strategy, Super Micro, Constellation Brands

Dow Jones
·
Jun 30

U.S. Research Roundup- Comcast, Honeywell Aerospace, Qualys

Reuters
·
Jun 30

Movement Alert|Abivax S.A. Rises 27.93% Overnight, Positive Phase 3 Maintenance Data Accelerates Safety Concern Recovery

Market Focus
·
Jun 30

Abivax Reports Positive Phase 3 Maintenance Data for Ulcerative Colitis Drug

MT Newswires Live
·
Jun 30

Movement Alert|Abivax S.A. Rises 21.37% in After-Hours Trading, Safety Controversy Digestion Fuels Rebound Momentum

Market Focus
·
Jun 30

Abivax announces results from ABTECT Maintenance Part 2

TIPRANKS
·
Jun 30

Abivax trading halted, news pending

TIPRANKS
·
Jun 30

NASDAQ Trade Halt Halt News Pending at 04:01 Pm

Reuters
·
Jun 30

European Equities Traded in the US as American Depositary Receipts Decline Friday

MT Newswires Live
·
Jun 26

Movement Alert|Abivax S.A. Rises 5.48% in Regular Trading, Bull-Bear Debate Intensifies Amid Phase 3 Trial Safety Controversy

Market Focus
·
Jun 26

Movement Alert|Abivax S.A. Falls 5.38% in After-Hours Trading, Phase 3 Trial Safety Controversy Continues to Suppress Rebound Momentum

Market Focus
·
Jun 26

Movement Alert|Abivax S.A. Falls 5.62% in Regular Trading, Phase 3 Trial Safety Concerns Continue to Suppress Rebound Momentum

Market Focus
·
Jun 26

Movement Alert|Abivax S.A. Overnight Decline 5.84%, Phase 3 Trial Safety Controversy Continues to Suppress Rebound

Market Focus
·
Jun 25

Movement Alert|Abivax S.A. Falls 5.15% in Regular Trading, Phase 3 Trial Safety Controversy Stalls Recovery Momentum

Market Focus
·
Jun 24

Abivax Sa : Jefferies Raises Target Price to $108 From $90

THOMSON REUTERS
·
Jun 22

U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, Visteon

Reuters
·
Jun 22